Cargando…

Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders

Lymphocytic colitis (LC) is a gastrointestinal (GI) tract disease with poorly known pathogenesis, but some environmental and lifestyle factors, including certain dietary components, may play a role. Tryptophan is an essential amino acid, which plays important structural and functional roles as a com...

Descripción completa

Detalles Bibliográficos
Autores principales: Chojnacki, Cezary, Gąsiorowska, Anita, Popławski, Tomasz, Błońska, Aleksandra, Konrad, Paulina, Zajdler, Radosław, Chojnacki, Jan, Blasiak, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097278/
https://www.ncbi.nlm.nih.gov/pubmed/37049514
http://dx.doi.org/10.3390/nu15071674
_version_ 1785024542072111104
author Chojnacki, Cezary
Gąsiorowska, Anita
Popławski, Tomasz
Błońska, Aleksandra
Konrad, Paulina
Zajdler, Radosław
Chojnacki, Jan
Blasiak, Janusz
author_facet Chojnacki, Cezary
Gąsiorowska, Anita
Popławski, Tomasz
Błońska, Aleksandra
Konrad, Paulina
Zajdler, Radosław
Chojnacki, Jan
Blasiak, Janusz
author_sort Chojnacki, Cezary
collection PubMed
description Lymphocytic colitis (LC) is a gastrointestinal (GI) tract disease with poorly known pathogenesis, but some environmental and lifestyle factors, including certain dietary components, may play a role. Tryptophan is an essential amino acid, which plays important structural and functional roles as a component of many proteins. It is important in the development and maintenance of the body, in which it is metabolized in two main pathways: kynurenine (KYN) and serotonin. In this work, we explored the effect of reducing of TRP in the diet of patients with LC with mood disorders. We enrolled 40 LC patients who had a normal diet, 40 LC patients with the 8-week diet with TRP content reduced by 25% and 40 controls. All LC patients received budesonide at 9 mg per day, and the severity of their GI symptoms was evaluated by the Gastrointestinal Symptoms Rating Scale. Mood disorders were evaluated by the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale (HAM-D). The concentration of TRP and its metabolites, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), kynurenic acid (KYNA) and quinolinic acid (QA), in urine were determined. Budesonide improved the GI and mental states of LC patients, and the diet with reduced TRP content further amended these symptoms. Dietary intervention decreased the concentration of 5-HIAA by about 50% (3.4 vs. 6.3) and QA by about 45% (3.97 vs. 7.20). These changes were correlated with a significant improvement in the profitable action of budesonide on gastrointestinal and mental health of LC patients as they displayed significantly lower GSRS, HAM-A and HAM-B scores after than before the intervention—10.5 vs. 32, 11.0 vs. 21 and 12 vs. 18, respectively. In conclusion, a reduction in TRP intake in diet may improve GI and mental symptoms in LC patients treated with budesonide and these changes may be mediated by the products of TRP metabolism.
format Online
Article
Text
id pubmed-10097278
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100972782023-04-13 Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders Chojnacki, Cezary Gąsiorowska, Anita Popławski, Tomasz Błońska, Aleksandra Konrad, Paulina Zajdler, Radosław Chojnacki, Jan Blasiak, Janusz Nutrients Article Lymphocytic colitis (LC) is a gastrointestinal (GI) tract disease with poorly known pathogenesis, but some environmental and lifestyle factors, including certain dietary components, may play a role. Tryptophan is an essential amino acid, which plays important structural and functional roles as a component of many proteins. It is important in the development and maintenance of the body, in which it is metabolized in two main pathways: kynurenine (KYN) and serotonin. In this work, we explored the effect of reducing of TRP in the diet of patients with LC with mood disorders. We enrolled 40 LC patients who had a normal diet, 40 LC patients with the 8-week diet with TRP content reduced by 25% and 40 controls. All LC patients received budesonide at 9 mg per day, and the severity of their GI symptoms was evaluated by the Gastrointestinal Symptoms Rating Scale. Mood disorders were evaluated by the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale (HAM-D). The concentration of TRP and its metabolites, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), kynurenic acid (KYNA) and quinolinic acid (QA), in urine were determined. Budesonide improved the GI and mental states of LC patients, and the diet with reduced TRP content further amended these symptoms. Dietary intervention decreased the concentration of 5-HIAA by about 50% (3.4 vs. 6.3) and QA by about 45% (3.97 vs. 7.20). These changes were correlated with a significant improvement in the profitable action of budesonide on gastrointestinal and mental health of LC patients as they displayed significantly lower GSRS, HAM-A and HAM-B scores after than before the intervention—10.5 vs. 32, 11.0 vs. 21 and 12 vs. 18, respectively. In conclusion, a reduction in TRP intake in diet may improve GI and mental symptoms in LC patients treated with budesonide and these changes may be mediated by the products of TRP metabolism. MDPI 2023-03-30 /pmc/articles/PMC10097278/ /pubmed/37049514 http://dx.doi.org/10.3390/nu15071674 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chojnacki, Cezary
Gąsiorowska, Anita
Popławski, Tomasz
Błońska, Aleksandra
Konrad, Paulina
Zajdler, Radosław
Chojnacki, Jan
Blasiak, Janusz
Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title_full Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title_fullStr Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title_full_unstemmed Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title_short Reduced Intake of Dietary Tryptophan Improves Beneficial Action of Budesonide in Patients with Lymphocytic Colitis and Mood Disorders
title_sort reduced intake of dietary tryptophan improves beneficial action of budesonide in patients with lymphocytic colitis and mood disorders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097278/
https://www.ncbi.nlm.nih.gov/pubmed/37049514
http://dx.doi.org/10.3390/nu15071674
work_keys_str_mv AT chojnackicezary reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT gasiorowskaanita reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT popławskitomasz reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT błonskaaleksandra reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT konradpaulina reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT zajdlerradosław reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT chojnackijan reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders
AT blasiakjanusz reducedintakeofdietarytryptophanimprovesbeneficialactionofbudesonideinpatientswithlymphocyticcolitisandmooddisorders